AKUS · Akouos, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q3 '21 | Q4 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $13.94M | $14.32M | $17.40M | - | $17.12M | $8.03M | - | $4.38M | $4.37M |
| SG&A | $6.27M | $6.68M | $5.51M | - | $5.67M | $2.50M | - | $887.0K | $2.66M |
| Total Operating Expenses | $20.20M | $21.00M | $22.91M | - | $22.78M | $10.54M | - | $13.12M | $12.60M |
| D&A | $800.0K | $800.0K | $700.0K | - | $500.0K | $446.0K | - | $100.0K | $500.0K |
| Operating Income | ($20.20M) | ($21.00M) | ($22.91M) | - | ($22.78M) | ($10.54M) | - | ($13.12M) | ($5.12M) |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - |
| Net Income | ($19.84M) | ($20.83M) | ($22.91M) | - | ($22.74M) | ($16.09M) | - | ($13.09M) | ($12.52M) |
| EPS - Basic | ($0.54) | ($0.58) | ($0.47) | - | - | - | - | - | - |
| EPS - Diluted | ($0.67) | ($0.58) | ($0.78) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q3 '21 | Q4 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75.41M | $73.58M | $54.38M | $121.91M | $131.31M | $120.17M | $68.93M | $35.54M | $333.00M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $562.0K | $679.0K | $1.33M | $1.28M | $1.07M | $992.0K | $895.0K | $817.0K | $339.0K |
| Current Assets | $174.49M | $194.92M | $211.45M | $236.16M | $274.03M | $291.04M | $310.64M | $322.23M | $334.04M |
| Total Assets | $225.51M | $244.54M | $255.96M | $278.75M | $316.58M | $321.86M | $333.35M | $342.25M | $45.16M |
| Current Liabilities | $10.09M | $14.59M | $18.56M | $16.80M | $12.08M | $7.06M | $10.71M | $8.62M | $9.23M |
| Long-term Debt | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $44.67M | $46.59M | $46.97M | $45.10M | $40.05M | $25.06M | $22.74M | $20.94M | $21.90M |
| Stockholders' Equity | $180.84M | $197.95M | $208.98M | $233.65M | $276.53M | $296.80M | $310.61M | $321.31M | ($13.11M) |
| Retained Earnings | ($236.05M) | ($216.21M) | ($195.38M) | ($168.40M) | ($120.55M) | ($97.81M) | ($81.72M) | ($69.18M) | ($33.12M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q3 '21 | Q4 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($20.06M) | - | - | ($8.58M) | - | - | - |
| Investing Cash Flow | - | - | ($47.69M) | - | - | ($1.03M) | - | - | - |
| Financing Cash Flow | - | - | $220.0K | - | - | $104.70M | - | - | - |
| CapEx | - | - | $2.79M | - | - | $1.03M | - | - | - |
| Free Cash Flow | - | - | ($22.85M) | - | - | ($9.61M) | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q3 '21 | Q4 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 1.00 | - | - | 0.60 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.8% | -8.5% | -8.9% | - | -7.2% | -5.0% | - | -3.8% | -27.7% |
| Return on equity | -11.0% | -10.5% | -11.0% | - | -8.2% | -5.4% | - | -4.1% | 95.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - |
| Liquidity | |||||||||
| Current ratio | 17.30 | 13.36 | 11.39 | 14.06 | 22.68 | 41.24 | 29.01 | 37.39 | 36.20 |
| Quick ratio | 17.30 | 13.36 | 11.39 | 14.06 | 22.68 | 41.24 | 29.01 | 37.39 | 36.20 |
| Cash ratio | 7.48 | 5.04 | 2.93 | 7.26 | 10.87 | 17.03 | 6.44 | 4.12 | 36.08 |
| Leverage | |||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.25 | 1.24 | 1.22 | 1.19 | 1.14 | 1.08 | 1.07 | 1.07 | -3.44 |
| Liabilities / Assets | 0.20 | 0.19 | 0.18 | 0.16 | 0.13 | 0.08 | 0.07 | 0.06 | 0.48 |
| Efficiency | |||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 11.8% | 7.8% | -74.6% | - | -345.4% | - | - | - | - |
| Net income growth (YoY) | 13.4% | 8.4% | -75.0% | - | -81.6% | - | - | - | - |
| EPS growth (YoY) | 14.1% | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -13.5% | -28.4% | -35.0% | -24.8% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Akouos against the 5 most active filers in the same SIC group.